Julie Smith
Director/Miembro de la Junta en EXELIXIS, INC. .
Fortuna: 128 121 $ al 30/04/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Michael Morrissey | M | 63 | 24 años | |
Stelios Papadopoulos | M | 75 | 30 años | |
Pamela Conley | M | - |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | - |
Adrian Krainer | M | 65 | 10 años | |
Seth Harrison | M | 63 | 9 años | |
Huw Nash | M | 57 | 10 años | |
Arthur Levin | M | 70 | 9 años | |
Sheldon Koenig | M | 58 |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | - |
Patrick Haley | M | 48 | 14 años | |
Jeffrey Hessekiel | M | 55 | 10 años | |
Peter Lamb | M | 63 | 24 años | |
Arthur Tzianabos | M | 60 | 6 años | |
Maria Freire | M | 69 | 6 años | |
Jennifer Burstein | F | 52 | 5 años | |
Jonathan Allan | M | - | - | |
Dana Aftab | M | - | 26 años | |
Garry Menzel | M | 59 | 4 años | |
Greg Coffey | M | - |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | - |
Susan T. Hubbard | F | - | 8 años | |
Ian Smith | M | 58 | 1 años | |
George Poste | M | 79 | 20 años | |
Jack Wyszomierski | M | 68 | 20 años | |
Edward Kaye | M | 75 | 7 años | |
Isabel Aznarez | M | 52 | 10 años | |
Hannah Chang | M | - |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | - |
Doug Snow | M | - | 3 años | |
Lindsay Treadway | F | - | - | |
Kenneth Harrison | M | 44 |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | - |
David Johnson | M | 41 | 1 años | |
Barry Ticho | M | 64 | 7 años | |
Laura Dillard | F | - | 19 años | |
Robert Oliver | M | 65 | 1 años | |
Stefan Krauss | M | - | 8 años | |
Amy Peterson | M | 57 | 1 años | |
Shamim Ruff | F | 64 | 6 años | |
Joan Wood | F | - | 5 años | |
Fulvio Mavilio | M | - | 7 años | |
Christopher Senner | M | 56 | 9 años | |
Tomas Jan Heyman | M | 68 | 1 años | |
Dawn Kalmar | F | 47 | 5 años | |
Eric Rojas | M | - | - | |
Mary Beckerle | M | 69 | - | |
S. Gail Eckhardt | M | 66 | - | |
Remsberg Heidi | F | - |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | 2 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Matt Patterson | M | 52 | 8 años | |
Scott Morrison | M | 66 |
ESCAPE Bio, Inc.
ESCAPE Bio, Inc. BiotechnologyHealth Technology ESCAPE Bio, Inc. is a preclinical stage biopharmaceutical company. It focuses on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. The company was founded by Robert Mahley and Yadong Huang in 2015 and is headquartered in San Francisco, CA. | 7 años |
Thomas Schuetz | M | 63 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 13 años |
George Scangos | M | 76 | 24 años | |
John Crowley | M | 57 |
Novazyme Pharmaceuticals, Inc.
Novazyme Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Novazyme Pharmaceuticals, Inc. researches and develops methods for modifying recombinantly produced enzymes. It develops a series of novel protein engineering technologies that have been shown in pre-clinical studies to greatly enhance the targeting and uptake of replacement enzymes. Novazyme's technologies also have application for developing advanced monoclonal antibodies and gene therapies. The company is located in Oklahoma City, OK. | 2 años |
Robert A. Heft | M | 69 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 7 años |
Jennifer Drimmer | F | - | 14 años | |
Eric Trachtenberg | M | 51 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 años |
Kush Parmar | M | 42 | 5 años | |
Joanne Quan | M | 60 |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | - |
Leon E. Chen | M | 49 |
ESCAPE Bio, Inc.
ESCAPE Bio, Inc. BiotechnologyHealth Technology ESCAPE Bio, Inc. is a preclinical stage biopharmaceutical company. It focuses on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. The company was founded by Robert Mahley and Yadong Huang in 2015 and is headquartered in San Francisco, CA. | - |
Mark Goldberg | M | 69 | 3 años | |
Jennifer Jarrett | F | 53 | 3 años | |
Edward Conner | M | 51 | 2 años | |
Thomas Woiwode | M | 52 | 4 años | |
Robin A. Walker | M | 55 | 1 años | |
Jacqueline Wright | F | 64 | 3 años | |
Edward Owens | M | 77 |
ESCAPE Bio, Inc.
ESCAPE Bio, Inc. BiotechnologyHealth Technology ESCAPE Bio, Inc. is a preclinical stage biopharmaceutical company. It focuses on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. The company was founded by Robert Mahley and Yadong Huang in 2015 and is headquartered in San Francisco, CA. | - |
Alan Garber | M | 68 | 19 años | |
Carl Feldbaum | M | 80 | 16 años | |
Charles M. Cohen | M | 73 | 27 años | |
Lance Willsey | M | 62 | 26 años | |
Stephen P. Squinto | M | 67 | 3 años | |
Louis Lange | M | 72 | 5 años | |
Jonathan Silverstein | M | 57 | 5 años | |
Vincent Marchesi | M | 88 | 22 años | |
Nancy M. Wyant | F | - | 5 años | |
Ted Harding | M | - |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 2 años |
Jason O’Byrne | M | 55 | 2 años | |
Andrew H. Chang | M | - | - | |
John Miller | M | - |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 años |
Toru Yoshimitsu | M | 61 | - | |
Vicki Goodman | M | 55 | 1 años | |
Mark Meltz | M | 50 | 1 años | |
Tracy M. Porter | F | - | 1 años | |
Justin Ford | M | - |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | 3 años |
Suyash Prasad | M | 54 | 5 años | |
Mary Reumuth | F | 48 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 años |
Bryan Cressey | M | 74 |
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA. | 6 años |
Christine Murray | F | 63 |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | 2 años |
Patrice Rioux | M | 73 |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | 5 años |
Michael Patrick Smith | M | 55 |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | 1 años |
Fredric D. Price | M | 78 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 6 años |
William J. Fallon | M | - |
Novazyme Pharmaceuticals, Inc.
Novazyme Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Novazyme Pharmaceuticals, Inc. researches and develops methods for modifying recombinantly produced enzymes. It develops a series of novel protein engineering technologies that have been shown in pre-clinical studies to greatly enhance the targeting and uptake of replacement enzymes. Novazyme's technologies also have application for developing advanced monoclonal antibodies and gene therapies. The company is located in Oklahoma City, OK. | 2 años |
Nathaniel M. Zilkha | M | 48 |
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA. | 4 años |
Anthony A. McKinney | M | 62 |
Novazyme Pharmaceuticals, Inc.
Novazyme Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Novazyme Pharmaceuticals, Inc. researches and develops methods for modifying recombinantly produced enzymes. It develops a series of novel protein engineering technologies that have been shown in pre-clinical studies to greatly enhance the targeting and uptake of replacement enzymes. Novazyme's technologies also have application for developing advanced monoclonal antibodies and gene therapies. The company is located in Oklahoma City, OK. | 1 años |
Sam Hall | M | 42 | 5 años | |
Heather McGaughey | F | - |
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA. | - |
Eric B. Mosbrooker | M | 46 | 2 años | |
Anne Borgman | M | 56 | 7 años | |
Jayant Aphale | M | 63 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 2 años |
Jeffrey C. Mack | M | - |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | - |
Krishna R. Polu | M | 50 |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | 1 años |
Ann Kapoun | M | - |
ESCAPE Bio, Inc.
ESCAPE Bio, Inc. BiotechnologyHealth Technology ESCAPE Bio, Inc. is a preclinical stage biopharmaceutical company. It focuses on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. The company was founded by Robert Mahley and Yadong Huang in 2015 and is headquartered in San Francisco, CA. | 1 años |
Sarah Spencer | F | - | 2 años | |
Joel Rothman | M | 55 |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | 2 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 92 | 92.00% |
Canadá | 9 | 9.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Julie Smith
- Red Personal